Transforming Parkinson's Care With Predictive Algorithms

ConditionParkinson

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorUniversity Ramon Llull

About this trial

Lifestyle interventions can alleviate Parkinson's Disease (PD) symptoms and delay disease progression. The novelty of this project lies in the development of an innovative smart platform that utilizes artificial intelligence (AI) and predictive models to offer a groundbreaking solution that not only prevents disease progression but also significantly improves the well-being of patients with PD. For this, the technological smart platform will encompass 50 clinical variables, and a comprehensive range of other 50 supplementary variables, validated in a database with more than 1500 patients. The smart platform will include a user-friendly interface with different user profiles and a scalable back end with AI-based monitoring and prediction modules. This will offer primary prevention, early detection, and ongoing monitoring by specialized medical professionals at home and in hospitals.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with Parkinson's disease

Disqualifiers

N/A

Trial population

Patients diagnosed with Parkinson's disease

Trial design

Design model

Ecologic or community

Time perspective

Prospective

Treatments tested in this trial

Lifestyle intervention
Other intervention
A technological smart platform (app) that integrates diets, physical activity programs, sleep habits and other lifestyle interventions

Treatment groups

200 Participants

are divided into 1 treatment group

Group A: Lifestyle intervention app1 intervention

Trial outcomes

Primary outcomes

Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

The MDS-UPDRS was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. The MDS-UPDRS has a total score range of 0 to 236, with individual parts scoring between 0 to 52 (Parts I and II), 0 to 108 (Part III), and 0 to 24 (Part IV), assessing both motor and non-motor aspects of Parkinson's disease. A higher score indicates greater severity of Parkinson's disease symptoms.

Time frame

From enrollment (app download) to 1 year

Secondary outcomes

Montreal Cognitive Assessment (MoCA)

The MoCA (Montreal Cognitive Assessment) scale has a total score range of 0 to 30, with higher scores indicating better cognitive function, and it assesses various cognitive domains such as memory, attention, language, and executive functions.

Time frame

At enrollment (app download) and after 1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Ramon Llull

Lead sponsor

University of Deusto

Collaborator

Hospital Universitari Vall d'Hebron Research Institute